Volume 6 - Special Issue 2 on COVID-19
Pharm Biomed Res 2020, 6 - Special Issue 2 on COVID-19: 111-116 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Abbaspour Kasgari H, Samaee H, Alian Samakkhah S, Moradimajd P. Treatment With Tocilizumab in a Patient With COVID-19. Pharm Biomed Res 2020; 6 (2) :111-116
URL: http://pbr.mazums.ac.ir/article-1-373-en.html
URL: http://pbr.mazums.ac.ir/article-1-373-en.html
1- Department of Clinical Pharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran.
2- Department of Infectious Diseases, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
3- Department of Anesthesia, Faculty of Allied Medical Sciences, Iran University of Medical Sciences, Tehran, Iran.
2- Department of Infectious Diseases, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
3- Department of Anesthesia, Faculty of Allied Medical Sciences, Iran University of Medical Sciences, Tehran, Iran.
Abstract: (1554 Views)
In late December 2019, a global outbreak (pandemic) of the coronavirus was reported, which WHO named 2019-nCoV. The virus is now spreading rapidly and has affected many countries, including Iran. There is no definitive and effective treatment for this virus yet. This report aimed to define the effect of Tocilizumab in patient with COVID-19. This case report is about a 52-year-old man with COVID-19 that has been treated with tocilizumab. The reported patient had an acceptable improvement in oxygen saturation but no significant change in lung CT scan. After 3 days treatment patient with Tocilizumab, extensive bilateral lungs involvement still exist but SPO2 level iimprovement up to 90%. According to the results, this drug had a positive impact on oxygen saturation. However, we cannot be certain whether this drug positively affected the patient’s coronavirus disease.
Type of Study: case report |
Subject:
Clinical Pharmacy
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC-By-NC), which permits use, distribution, and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Contact Information
